A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity. Hagemann CA, Legart C, Mollerhoj MB, Madsen MR, et al. PLoS One 2022;17:e0275901.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Hagemann CA, Legart C, Mollerhoj MB, Madsen MR, et al. A liver secretome gene signature-based approach for determining circulating biomarkers of NAFLD severity. PLoS One 2022;17:e0275901.
PMID: 36260611